Indication

ONUREG (azacitidine) is an oral prescription medicine used to treat adults with acute myeloid leukemia (AML) who are in first complete remission (CR) (with or without recovery of your blood cell counts) after intensive induction chemotherapy and are not able to complete intensive curative therapy. It is not known if ONUREG is safe and effective in children under 18 years of age.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia Version 3.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed July 3, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

 



 

Important Safety Information     Contact Us     Privacy Policy   Your Privacy Choices    Legal Notice     Site Map

This site is intended for U.S. residents 18 years of age or older.

BMS logo

© 2024 Bristol-Myers Squibb Company. All rights reserved.
ONUREG® is a registered trademark of Celgene Corporation, a Bristol-Myers Squibb company.
BMS Access Support® is a registered trademark of Bristol-Myers Squibb Company.
2011-US-2400182 10/24